ImmunoCellular Therapeutics (IMUC) 10-K 14 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 28, 2014	Jun. 30, 2013
Document - Document and Entity Information [Line Items]	'	'	'
Entity Registrant Name	'ImmunoCellular Therapeutics, Ltd.	'	'
Entity Central Index Key	'0000822411	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Document Fiscal Year Focus	'2013	'	'
Document Fiscal Period Focus	'FY	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Filer Category	'Accelerated Filer	'	'
Entity Public Float	'	'	$103,973,710
Entity Common Stock, Shares Outstanding	'	57,565,704	'

Balance_Sheets

Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$27,646,351	$26,216,668
Other assets	763,299	714,508
Total current assets	28,409,650	26,931,176
Property and equipment, net	66,442	76,289
Other assets	464,585	11,736
Total assets	28,940,677	27,019,201
Current liabilities:	'	'
Accounts payable	861,026	732,851
Accrued compensation and benefits	357,265	309,345
Accrued liabilities	183,982	56,111
Total current liabilities	1,402,273	1,098,307
Warrant Liability	1,064,810	2,852,880
Commitments and contingencies (Note 5)	'	'
Shareholders’ equity:	'	'
Common stock, $0.0001 par value; 149,000,000 shares and 99,000,000 shares authorized as of December 31, 2013 and 2012 respectively; 57,542,231 shares and 51,500,996 shares issued and outstanding as of December 31, 2013 and 2012, respectively	5,754	5,150
Additional paid-in capital	78,437,233	66,231,694
Deficit accumulated during the development stage	-51,969,393	-43,168,830
Total shareholders’ equity	26,473,594	23,068,014
Total liabilities and shareholders’ equity	$28,940,677	$27,019,201

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	149,000,000	99,000,000
Common stock, shares issued	57,542,231	51,500,996
Common stock, shares outstanding	57,542,231	51,500,996

Statements_of_Operations

Statements of Operations (USD $)	12 Months Ended			118 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Revenues	'	'	'	$300,000
Expenses:	'	'	'	'
Research and development	5,339,716	7,711,233	4,988,612	23,599,829
Stock based compensation	724,212	496,007	1,190,133	9,440,224
General and administrative	3,396,391	3,619,291	2,446,757	16,081,138
Total expenses	9,460,319	11,826,531	8,625,502	49,121,191
Loss before other income (expense) and income taxes	-9,460,319	-11,826,531	-8,625,502	-48,821,191
Interest income	17,345	8,609	4,346	365,089
Financing expense	'	-397,294	'	-397,294
Change in fair value of warrant liability	642,411	-2,279,923	2,901,253	-1,023,497
Loss before income taxes	-8,800,563	-14,495,139	-5,719,903	-49,876,893
Income taxes	'	'	'	'
Net loss	-8,800,563	-14,495,139	-5,719,903	-49,876,893
Deemed dividend on redemption of preferred stock	'	'	'	-2,092,500
Net loss attributable to common stockholders	($8,800,563)	($14,495,139)	($5,719,903)	($51,969,393)
Net loss per share basic and diluted	($0.16)	($0.35)	($0.21)	($2.55)
Weighted average number of shares basic and diluted	54,281,189	41,797,048	27,450,559	20,405,284

Statements_of_Shareholders_Equ

Statements of Shareholders' Equity (Deficit) (USD $)

Total

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

Common Stock 0.19 Per Share

Common Stock 0.19 Per Share

Common Stock 0.19 Per Share

Common Stock 0.19 Per Share

Common Stock 0.19 Per Share

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock 0.32 Per Share

Common Stock 0.32 Per Share

Common Stock 0.32 Per Share

Common Stock 0.32 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Research and Development 0.99 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Services 0.50 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 1.00 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.57 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.57 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.57 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.57 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.57 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.57 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.79 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.79 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.79 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.79 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.79 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.79 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.90 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.90 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.90 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.90 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.90 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.90 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

Preferred Stock

Common Stock

Additional Paid-in Capital

Promissory Note

Deficit Accumulated During the Development Stage

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Balance at Feb. 24, 2004

$97

$0

$10

$87

$0

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Feb. 24, 2004

'

0

6,256,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash

150

0

15

135

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

193,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-11,741

'

'

'

'

-11,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2004

-11,494

0

25

222

0

-11,741

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2004

'

'

6,450,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash

'

'

'

'

'

'

75,000

0

659

74,341

0

0

50,000

0

16

49,984

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

'

'

'

'

'

'

387,000

'

'

'

'

'

154,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-246,004

'

'

'

'

-246,004

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements, net of redemptions

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

152,760

0

15

152,745

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements, net of redemptions, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

154,800

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2005

20,262

0

715

277,292

0

-257,745

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2005

'

'

7,146,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,152,713

'

'

'

'

-5,152,713

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements, net of redemptions

549,400

0

151

549,249

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash in private placements, net of redemptions, shares

'

'

1,510,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

36,546

0

7

36,539

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

73,093

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

694,000

0

69

693,931

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

694,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in connection with reverse merger

'

0

83

-83

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares issued in connection with reverse merger, shares

'

'

825,124

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares cancelled in connection with the sale of Optical Molecular Imaging, Inc.

-65,000

0

-206

-64,794

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares cancelled in connection with the sale of Optical Molecular Imaging, Inc., Shares

'

'

-2,059,100

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

3,522

0

1

3,521

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

10,062

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

4,103,645

'

'

4,103,645

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2006

189,662

0

820

5,599,300

0

-5,410,458

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2006

'

'

8,199,779

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash

4,892,486

0

353

4,892,133

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

3,531,603

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,614,753

'

'

'

'

-3,614,753

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

'

0

5

-5

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

51,111

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

1,296,714

'

'

1,296,714

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of warrant derivative liability

2,233,600

'

'

2,233,600

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2007

4,997,709

0

1,178

14,021,742

0

-9,025,211

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2007

'

'

11,782,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-3,059,730

'

'

'

'

-3,059,730

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

424,000

0

80

423,920

0

0

65,000

0

10

64,990

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

800,000

'

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

513,357

'

'

513,357

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2008

2,940,336

0

1,268

15,024,009

0

-12,084,941

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2008

'

'

12,682,493

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-2,626,205

'

'

'

'

-2,626,205

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

11,814

0

22

64,460

-52,668

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

214,357

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

308,302

'

'

308,302

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

462,748

0

197

462,551

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants, shares

'

'

1,970,992

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2009

1,096,995

0

1,487

15,859,322

-52,668

-14,711,146

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2009

'

'

14,867,842

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-6,150,142

'

'

'

'

-6,150,142

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

54,000

0

6

53,994

0

0

8,156

0

'

8,156

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60,000

'

'

'

'

'

7,694

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

26,500

0

5

26,495

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

745,697

'

'

745,697

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, net of offering costs

3,248,738

0

423

3,248,315

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, net of offering costs, shares

'

'

4,230,910

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock and warrants issued for cash, net of offering costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock and warrants issued for cash, net of offering costs, shares

'

400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants in exchange for promissory note

'

0

270

5,399,730

-5,400,000

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants in exchange for promissory note, shares

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of preferred stock for repayment of promissory note

3,307,500

'

'

'

5,400,000

-2,092,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of preferred stock for repayment of promissory note, shares

'

-400

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

'

0

30

-30

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

297,156

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest on promissory note

-1,614

'

'

'

-1,614

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2010

2,335,830

0

2,221

25,341,679

-54,282

-22,953,788

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2010

'

'

22,213,602

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-5,719,903

'

'

'

'

-5,719,903

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

388,379

0

38

388,341

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

1,269,767

'

382,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

1,190,133

0

13

1,190,120

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

131,537

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, net of offering costs

4,983,339

0

522

4,982,817

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, net of offering costs, shares

'

'

5,219,768

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

'

0

67

-67

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

667,077

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest on promissory note

-352

'

'

'

-352

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Redemption of promissory note

54,634

'

'

'

54,634

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2011

3,232,060

0

2,861

31,902,890

0

-28,673,691

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2011

'

'

28,613,984

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-14,495,139

'

'

'

'

-14,495,139

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

20,500

0

2

20,498

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

1,285,384

'

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

496,007

'

'

496,007

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reclassification of warrant derivative liability

1,981,743

'

'

1,981,743

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

3,201,920

0

230

3,201,690

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants, shares

'

'

2,295,334

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, net of offering costs

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,271,370

0

949

9,270,421

0

0

19,359,553

0

1,000

19,358,553

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, net of offering costs, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

9,489,436

'

'

'

'

'

10,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

'

0

79

-79

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

792,018

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants

'

0

29

-29

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants shares

'

'

288,973

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted stock vested, shares

'

'

1,251

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at Dec. 31, 2012

23,068,014

0

5,150

66,231,694

0

-43,168,830

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2012

'

'

51,500,996

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Net loss

-8,800,563

'

'

'

'

-8,800,563

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options

324,517

0

53

324,464

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of stock options, shares

829,702

'

528,702

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options)

724,212

'

'

724,212

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation (options), shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants

6,176,336

0

344

6,175,992

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise of warrants, shares

'

'

3,441,551

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options

'

0

15

-15

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of stock options, shares

'

'

149,385

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants

'

0

3

-3

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cashless exercise of warrants shares

'

'

31,155

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for license rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

75,000

0

3

74,997

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for license rights, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

28,300

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued through controlled equity offering

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

404,191

0

17

404,174

0

0

2,013,124

0

77

2,013,047

0

0

1,752,338

0

64

1,752,274

0

0

736,425

0

28

736,397

0

0

Common stock issued through controlled equity offering, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

172,988

'

'

'

'

'

770,508

'

'

'

'

'

642,604

'

'

'

'

'

276,042

'

'

'

Balance at Dec. 31, 2013

$26,473,594

$0

$5,754

$78,437,233

$0

($51,969,393)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance, shares at Dec. 31, 2013

'

'

57,542,231

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Statements_of_Shareholders_Equ1

Statements of Shareholders' Equity (Deficit) (Parenthetical) (USD $)

12 Months Ended

Dec. 31, 2013

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2005

Dec. 31, 2005

Dec. 31, 2008

Dec. 31, 2008

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Common Stock 0.19 Per Share

Common Stock 0.32 Per Share

Common Stock Issued for Research and Development 0.53 Per Share

Common Stock Issued for Research and Development 0.65 Per Share

Common Stock Issued for Services 0.90 Per Share

Common Stock Issued for Services 1.06 Per Share

Common Stock and Warrants Issued for Cash 1.1 Per Share

Common Stock and Warrants Issued for Cash 2.1 Per Share

Common Stock Issued For License Rights 2.41 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.57 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.79 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.90 Per Share

Common Stock Issued Through Controlled Equity Offering At An Average Of 2.84 Per Share

Initial capitalization, per share

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, per share

$0.00

'

'

'

'

'

$0.19

$0.32

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for research and development, per share

'

'

'

'

$1

$0.99

'

'

$0.53

$0.65

'

'

'

'

'

'

'

'

'

Common stock issued for services, per share

'

'

'

'

$0.50

'

'

'

'

'

$0.90

$1.06

'

'

$2.41

'

'

'

'

Common stock issued for cash in private placements, per share

'

'

'

$1.50

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock and warrants issued for cash, per share

'

$1.55

$1

'

'

'

'

'

'

'

'

'

$1.10

$2.10

'

'

'

'

'

Preferred stock and warrants issued for cash, per share

'

'

$10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued through controlled equity offering at an average, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.57

$2.79

$2.90

$2.84

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	12 Months Ended			118 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Cash flows from operating activities:	'	'	'	'
Net loss	($8,800,563)	($14,495,139)	($5,719,903)	($49,876,893)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'	'
Depreciation and amortization	50,402	45,823	20,357	125,687
Interest accrued on promissory note	'	'	1,264	'
Loss on disposal of assets	3,817	'	'	3,817
Change in fair value of warrant liability	-642,411	2,279,923	-2,901,253	1,023,497
Financing expense	'	397,294	'	397,294
Stock-based compensation	724,212	496,007	1,190,133	9,378,068
Common stock issued for services	'	'	'	98,703
Common stock issued for research and development	'	'	'	1,335,760
Changes in assets and liabilities:	'	'	'	'
Other assets	-426,640	-623,538	-105,581	-1,219,047
Accounts payable	128,175	-401,090	962,876	860,676
Accrued liabilities	175,791	-79,293	168,365	541,247
Net cash used in operating activities	-8,787,217	-12,380,013	-6,383,742	-37,331,191
Cash flows from investing activities:	'	'	'	'
Purchase of property and equipment	-44,372	-9,828	-84,392	-200,064
Cash paid for sale of Optical Molecular Imaging, Inc.	'	'	'	-25,000
Net cash used in investing activities	-44,372	-9,828	-84,392	-225,064
Cash flows from financing activities:	'	'	'	'
Proceeds from exercise of stock options	324,517	20,500	388,379	775,230
Proceeds from exercise of warrants	5,030,677	3,201,918	'	8,695,343
Payments on promissory note receivable	'	'	53,018	53,018
Proceeds from issuance of common stock and warrants net of offering costs	4,906,078	28,730,923	7,360,129	51,899,857
Proceeds from issuance of preferred stock and warrants, net of offering costs	'	'	'	3,779,158
Net cash provided by financing activities	10,261,272	31,953,341	7,801,526	65,202,606
Increase in cash and cash equivalents	1,429,683	19,563,500	1,333,392	27,646,351
Cash and cash equivalents, beginning of period	26,216,668	6,653,168	5,319,776	'
Cash and cash equivalents, end of period	27,646,351	26,216,668	6,653,168	27,646,351
Supplemental cash flows disclosures:	'	'	'	'
Interest expense paid	'	'	'	'
Income taxes paid	'	'	'	'
Supplemental non-cash financing disclosures:	'	'	'	'
Exercise of warrants in exchange for promissory note	'	'	'	3,350,000
Redemption of preferred stock for repayment of promissory note	'	'	'	3,350,000
Deemed dividend on redemption of preferred stock	'	'	'	2,092,500
Warrant liability converted to additional paid-in capital	1,145,659	1,981,745	'	3,127,404
Deposits used to acquire property and equipment	'	35,882	'	35,882
Deferred offering costs	'	'	182,599	182,599
Common stock issued for license rights	$75,000	'	'	$75,000

Nature_of_Organization_and_Dev

Nature of Organization and Development Stage Operations	12 Months Ended
	Dec. 31, 2013
Nature of Organization and Development Stage Operations	'
	1	Nature of Organization and Development Stage Operations
	ImmunoCellular Therapeutics, Ltd. (the Company) is a development stage company that is seeking to develop and commercialize new therapeutics to fight cancer using the immune system.
	The Company has been primarily engaged in the acquisition of certain intellectual property, together with development of its product candidates and the recent clinical testing activities for one of its vaccine product candidates, and has not generated any recurring revenues. The Company’s lead product candidate, ICT-107, is in Phase II clinical development. The Company has two other product candidates, ICT-140 and ICT-121, both with investigational new drug (IND) applications active at the US Food and Drug Administration (FDA). The Company has incurred operating losses and, as of December 31, 2013, the Company had an accumulated deficit of $51,969,393. The Company expects to incur significant research, development and administrative expenses before any of its products can be launched and recurring revenues generated.
	On January 31, 2006, we completed a merger pursuant to which Spectral Molecular Imaging, Inc. became our wholly owned subsidiary. At the time of the merger, we had virtually no assets or liabilities, and we had not conducted any business operations for several years. In connection with the merger, we changed our name from Patco Industries, Ltd. to Optical Molecular Imaging, Inc. and replaced our officers and directors with those of Spectral Molecular Imaging. Although we acquired Spectral Molecular Imaging in the merger, for accounting purposes the merger was treated as a reverse merger since the stockholders of Spectral Molecular Imaging acquired a majority of our outstanding shares of common stock and the directors and executive officers of Spectral Molecular Imaging became our directors and executive officers. Accordingly, our financial statements contained in this Report and the description of our results of operations and financial condition reflect the operations of Spectral Molecular Imaging from its inception on February 25, 2004.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Summary of Significant Accounting Policies	'
	2	Summary of Significant Accounting Policies
	Development Stage Enterprise—The Company is a development stage enterprise and is devoting substantially all our present efforts to research and development. All losses accumulated since inception are considered part of the Company’s development stage activities.
	Liquidity —As of December 31, 2013, the Company had working capital of $27,007,377, compared to working capital of $25,832,869 as of December 31, 2012. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient for this purpose.
	Cash and cash equivalents—The Company considers all highly liquid instruments with an original maturity of 90 days or less to be cash equivalents. As of December 31, 2013 and December 31, 2012, the Company had $25,913,893 and $23,646,922, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments..
	Property and Equipment—Property and equipment are stated at cost and depreciated using the straight-line methods based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
	Research and Development Expenses—Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred.
	Stock Based Compensation—The Company records the cost for all share-based payment transactions in the Company’s financial statements.
	Stock option grants issued prior to March 31, 2011 to employees and officers and directors were valued using the Black-Scholes pricing model. Stock option grants made subsequent to March 31, 2011 were valued using the binomial lattice simulation model.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
			Year			Year			Year
			Ended			Ended			Ended
			December 31,			December 31,			December 31,
			2013			2012			2011
	Risk-free interest rate			1.64	%		0.49	%		1.89	%
	Expected dividend yield			None			None			None
	Expected life			5.21 years			4.40 years			5.8 years
	Expected volatility			90.58	%		66.1	%		64	%
	Expected forfeitures			0	%		0	%		0	%
	The weighted-average grant-date fair value of options granted during the year ended December 31, 2013, 2012 and 2011 was $1.89, $1.29 and $0.98, respectively.
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the year ended December 31, 2013, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue previously unissued shares of common stock to satisfy share option exercises. As of December 31, 2013, the Company had 56,617,707 shares of authorized but unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.
	Income Taxes—The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of December 31, 2013 and 2012, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2013, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2009 for the state and December 31, 2010 for the federal taxing authority.
	Fair Value of Financial Instruments—The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1 - quoted prices in active markets for identical assets or liabilities
	Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 - inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
	Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
	The following critical accounting policies affect the company’s more significant judgments and estimates used in the preparation of these financial statements:
	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2013, 2012 and 2011, remain open for possible review.
	Warrant liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.
	Basic and Diluted Net Loss per Common Share—Basic and diluted net loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per share for the years ended December 31, 2013, 2012 and 2011, since the effect would be antidilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted net loss per share, totaled 26,108,984, 24,139,760 and 17,405,930 shares at December 31, 2013, 2012 and 2011, respectively.
	Recently Issued Accounting Standards— In June 2011, the Financial Accounting Standards Board (FASB) issued ASU No. 2011-5, which amends the Comprehensive Income Topic of the ASC. The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders’ equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements. ASU No. 2011-5 became effective for interim and annual periods beginning after December 15, 2011. In February 2013, the FASB issued ASU No. 2013-02, which further amends the Comprehensive Income Topic of the ASC. This amendment requires entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount is being reclassified in its entirety to net income. This standard became effective for periods beginning after December 15, 2012. The adoption of these ASU’s did not have a material impact on the Company’s results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future condensed financial statements.

Property_and_Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2013
Property and Equipment	'
	3	Property and Equipment
	Property and equipment consist of the following:
			December 31,			December 31,
			2013			2012
	Computers		$	67,566		$	23,192
	Research equipment			117,809			128,381
				185,375			151,573
	Accumulated depreciation			(118,933	)		(75,284	)
			$	66,442		$	76,289
	Depreciation expense was $50,402, $45,823 and $20,357 for the years ended December 31, 2013, 2012 and 2011, respectively. Depreciation expense was $125,687 for the period from February 25, 2004 (date of inception) to December 31, 2013.

RelatedParty_Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2013
Related-Party Transactions	'
	4	Related-Party Transactions
	Cedars-Sinai Medical Center License Agreement
	Dr. John Yu, our Chief Scientific Officer and former interim Chief Executive Officer, is a neurosurgeon at Cedars-Sinai Medical Center (Cedars-Sinai). In November 2006, the Company entered into a license agreement with Cedars-Sinai under which the Company acquired an exclusive, worldwide license to its technology for use as cellular therapies, including cancer stem cell and dendritic cell-based vaccines for neurological disorders that include brain tumors and neurodegenerative disorders and other cancers. This technology is covered by a number of pending U.S. and foreign patent applications, and the term of the license will be until the last to expire of any patents that are issued covering this technology.
	As an upfront licensing fee, the Company issued Cedars-Sinai 694,000 shares of its common stock and paid Cedars-Sinai $62,000. Additional specified milestone payments will be required to be paid to Cedars-Sinai when the Company initiates patient enrollment in its first Phase III clinical trial and when it receives FDA marketing approval for its first product.
	The Company has agreed to pay Cedars-Sinai specified percentages of all of its sublicensing income and gross revenues from sales of products based on the licensed technology. To maintain its rights to the licensed technology, the Company must meet certain development and funding milestones. These milestones include, among others, commencing a Phase I clinical trial for a product candidate by March 31, 2007 and raising at least $5,000,000 in funding from equity or other sources by December 31, 2008. The Company satisfied the foregoing funding requirement in 2007 and commenced a Phase I clinical trial in May 2007, which was within the applicable cure period for the milestone requirement. Through December 31, 2009, the Company has paid Cedars-Sinai a total of $166,660 in connection with the Phase I clinical trial. The Company also was required to commence a Phase II clinical trial for a product candidate by December 31, 2008 and a waiver of this requirement was obtained from Cedars-Sinai (see Second Amendment below).
	On June 16, 2008, the Company entered into a First Amendment to Exclusive License Agreement (the Amendment) with Cedars-Sinai. The Amendment amended the License Agreement to include in the Company’s exclusive license from Cedars-Sinai under that agreement an epitope to CD133 and certain related intellectual property. This technology is covered by U.S. patent applications filed by both parties. Pursuant to the Amendment, the Company issued Cedars-Sinai 100,000 shares of the Company’s common stock as an additional license fee for the licensed CD133 epitope technology, which will be subject to the royalty and other terms of the License Agreement.
	On July 22, 2009, the Company entered into a Second Amendment to Exclusive License Agreement (the Second Amendment) with Cedars-Sinai to become effective August 1, 2009. The Second Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase II clinical trial for the Company’s first product candidate by no later than December 31, 2008 with milestones that require commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012.
	Effective March 23, 2010, the Company entered into a Third Amendment to Exclusive License Agreement (the Third Amendment) with Cedars-Sinai. The Third Amendment amended the License Agreement to revise the milestones set forth in the License Agreement that the Company must achieve in order to maintain its license rights under that agreement. The revised milestones include the replacement of a milestone that required commencement of a Phase I clinical trial for the Company’s second product candidate by no later than June 30, 2010 and commencement of a Phase II clinical trial for one of the Company’s product candidates by no later than March 31, 2012 with a requirement that the Company by September 30, 2011 either commence a Phase II clinical trial for its dendritic cell vaccine candidate or a Phase I clinical trial for its cancer stem cell vaccine candidate. The amendment also added a requirement that the Company obtain certain defined forms of equity or other funding in the amount of at least $2,500,000 by December 31, 2010 and a total of at least $5,000,000 by September 30, 2011. These funding requirements were fully satisfied as of June 30, 2011.
	Effective September  20, 2010, the Company entered into a sponsored research agreement with Cedars-Sinai under which Cedars-Sinai provided services to the Company in developing the ICT-121 vaccine at a total cost of $446,142.  Effective September 20, 2011, the Company entered into Amendment No. 1 extending the agreement to September 19, 2012 at an incremental cost of $294,504.  Effective September 20, 2012, the Company entered into Amendment No. 2 extending the agreement to September 19, 2013 at an incremental cost of $329,832.  This agreement concluded on September 19, 2013 but was extended through March 19, 2014 at a projected incremental cost of $210,856.

Commitments_and_Contingencies

Commitments and Contingencies

12 Months Ended

Dec. 31, 2013

Commitments and Contingencies

'

5

Commitments and Contingencies

Sponsored Research Agreements

In an effort to expand the Company’s intellection property portfolio to use antigens to create personalized vaccines, the Company has entered into various intellectual property and research agreements. Those agreements are long-term in nature and are discussed below.

Aptiv Solutions

The Company has contracted with Aptiv Solutions to provide certain services related to the Company’s ICT-107 Phase II trial. The original agreement was entered into in August of 2010 and provided for estimated payments of approximately $3 million for services through September 2013. Subsequently, the Company and Aptiv entered into three contract amendments. Under the first amendment, effective January 20, 2011, Aptiv agreed to provide additional services in conjunction with the Phase II trial of ICT-107 for an additional fee of $469,807. The second amendment, effective February 4, 2012, extended the services to be provided by Aptiv and further increased the fees by $986,783. The second amendment also extended the term of the agreement to March 31, 2014. On January 11, 2013, the third amendment was finalized whereby the services were further extended and the fees were further increased by $608,201. The total aggregate fee pursuant to the original agreement and the three modifications is $5,078,169.

On September 17, 2013, the Company entered into a Master Services Agreement with Aptiv Solutions to provide certain services related to the Company’s ICT-140 Phase II trial.  The related Project Agreement Number 1 entered into on September 17, 2013  provided for estimated payments of approximately $2.7 million until completion of the services described therein.

As of December 31, 2013, the Company’s remaining obligation under the existing commitments is approximately $3.1 million.

University of Pennsylvania

On February 13, 2012, the Company entered into a Patent License Agreement with The Trustees of the University of Pennsylvania under which the Company acquired an exclusive, world-wide license relating to patent technology for the production, use and cryopreservation of high-activity dendritic cell cancer vaccines

Pursuant to the License Agreement, the Company paid an upfront licensing fee and will be obligated to pay annual license maintenance fees. In addition, the Company has agreed to make payments upon completion of specified milestones and to pay royalties of a specified percentage on net sales, subject to a specified minimum royalty, and sublicensing fees on product sales covered by the license.

The John Hopkins University Licensing Agreement

On February 23, 2012, the Company entered into an Exclusive License Agreement, effective as of February 16, 2012, with The John Hopkins University (JHU) under which it received an exclusive, world-wide license to JHU’s rights in and to certain intellectual property related to mesothelin-specific cancer immunotherapies.

Pursuant to the License Agreement, the Company agreed to pay an upfront licensing fee, payable half in cash and half in shares of its common stock, within 30 days of the effective date of the License Agreement and upon issuance of the first U.S. patent covering the subject technology. In addition, the Company has agreed to pay milestone license fees upon completion of specified milestones, customary royalties based on a specified percentage of net sales, sublicensing payments and annual minimum royalties. Effective September 24, 2013, the Company entered into an Amendment No. 1 to the Exclusive License Agreement that updated certain milestones.

The University of Pittsburgh Patent License Agreement

On March 20, 2012, the Company entered into an Exclusive License Agreement with the University of Pittsburgh under which the Company has licensed intellectual property surrounding EphA2, a tyrosine kinase receptor that is highly expressed by ovarian cancer and other advanced and metastatic malignancies. The License Agreement grants a world-wide exclusive license to the intellectual property for ovarian and pancreatic cancers; and a world-wide non-exclusive license to the intellectual property for brain cancer.

Pursuant to the License Agreement, the Company agreed to pay an upfront nonrefundable and noncreditable licensing fee and nonrefundable and noncreditable maintenance fees due annually starting 12 months from the anniversary of the effective date of the License Agreement. In addition, the Company has agreed to make certain milestone payments upon completion of specified milestones and to pay customary royalties based on a specified percentage of net sales and sublicensing payments, as applicable.

Torrey Pines

On October 1, 2012, the Company entered into a Contract Services Agreement with Torrey Pines under which the Company has engaged Torrey Pines to determine the immunogenicity of certain peptides that are used in conjunction with the Company’s ICT-107 Phase II trial and in the development of ICT-140. The Company agreed to pay an upfront nonrefundable and noncreditable fee and is obligated to pay the remainder at the conclusion of the contract. On April 1, 2013, the Company and Torrey Pines expanded the scope of work to be completed by Torrey Pines under an additional Contract Services Agreement. This supplemental agreement provides for the Company to pay an upfront fee and additional fees at the conclusion of the contract.

Cedars-Sinai Medical Center

In connection with the Cedars-Sinai Medical Center License Agreement, the Company has certain commitments as described in Note 4.

Employment Agreement with Andrew Gengos

On December 3, 2012, the Company entered into an Agreement with Andrew Gengos pursuant to which Mr. Gengos serves as the Company’s President and Chief Executive Officer. The Agreement may be terminated be either party with or without cause. The Agreement provides for an annual base salary of $400,000. Additionally, beginning in 2013, Mr. Gengos was eligible for an annual discretionary bonus of up to 40% of his base annual salary as determined by the Company’s Board of Directors.

On December 3, 2012, Mr. Gengos was granted a seven-year option to purchase 700,000 shares of the Company’s common stock at a price of $2.13 per share vesting in one annual installment of 175,000 shares on December 2, 2013 and in 36 equal monthly installments thereafter. The vesting of the stock options will accelerate such that the stock options will be fully vested on his last day of employment. The options may be exercised during Mr. Gengos’ employment with the Company and for 90 days after termination for any reason except termination without cause by Mr. Gengos or termination for cause by the Company, provided that such exercise is within the seven-year term of the option.

In the event the Company terminates Mr. Gengos’ employment without cause, or in the event Mr. Gengos resigns for good cause, Mr. Gengos will be entitled to severance equal to one-year of Mr. Gengos’ base salary in effect at the date of termination. Additionally, the Company will pay Mr. Gengos’ COBRA premiums for a period of up to one year.

Employment Agreement with Dr. John Yu

On May 10, 2011, the Company entered into an Agreement, effective as of March 1, 2011, with Dr. John Yu pursuant to which Dr. Yu continues to serve as the Company’s Chief Scientific Officer. The term of this Agreement automatically renews on the one-year anniversary date of the Agreement each year after March 1, 2011 for successive one-year terms unless either party terminates. Dr. Yu may also terminate the Agreement at any time upon 60 days notice. The Agreement was automatically renewed on March 1, 2012 and March 1, 2013. Under this agreement, Dr. Yu currently receives an annual salary of $125,000. Additionally, Dr. Yu is eligible for a discretionary cash bonus.

On March 1, 2011, Dr. Yu was granted a seven-year option to purchase 50,000 shares of the Company’s common stock at a price of $1.95 per share vesting in three equal annual installments beginning on February 29, 2012.  The option may be exercised during the term that Dr. Yu provides services to the Company and for twelve months after termination for any reason except termination without cause by Dr. Yu or termination for cause by the Company, provided that such exercise is within the seven-year term of the option.  On June 14, 2013, Dr. Yu was granted a five-year option to purchase 45,000 shares of the Company’s common stock at a price of $2.19 per share vesting in equal monthly installments over a four-year term beginning on March 1, 2013.   All of the options granted to Dr. Yu will vest if his services terminate following a merger or similar corporate transaction in which the Company is not the surviving entity and the surviving entity does not offer Dr. Yu an executive position at a compensation level at least equal to his then compensation level under the Agreement.

Employment Agreement with Anthony Gringeri

On August 19, 2013, the Company entered into an Agreement with Anthony Gringeri pursuant to which Dr. Gringeri serves as the Company’s Senior Vice President of Strategic Resources. The Agreement may be terminated be either party with or without cause. The Agreement provides for an annual base salary of $310,000. Additionally, Dr. Gringeri is eligible for an annual discretionary bonus of up to 30% of his base annual salary, prorated for 2013, as determined by the Company’s Board of Directors.

On September 20, 2013, Dr. Gringeri was granted a ten-year option to purchase 300,000 shares of the Company’s common stock at a price of $2.70 per share vesting in one annual installment of 75,000 shares on September 20, 2014 and in 36 equal monthly installments thereafter. The vesting of the stock options will accelerate such that the stock options vesting within six months of termination will be fully vested on his last day of employment. The options may be exercised during Dr. Gringeri’s employment with the Company and for 90 days after termination for any reason except termination without cause by Dr. Gringeri or termination for cause by the Company, provided that such exercise is within the ten-year term of the option.

In the event the Company terminates Dr. Gringeri’s employment without cause, or in the event Dr. Gringeri resigns for good cause, Dr. Gringeri will be entitled to severance equal to six months of Dr. Gringeri’s base salary in effect at the date of termination. Additionally, the Company will pay Dr. Gringeri’s COBRA premiums for a period of up to six months.

Employment Agreement with David Fractor

On April 4, 2011, the Company entered into an Employment Agreement with David Fractor pursuant to which Mr. Fractor serves as the Company’s Vice President of Finance and Principal Accounting Officer on a part-time basis for a three-year term, subject to termination by either party on 30 days notice. Under this agreement, Mr. Fractor currently receives an annual salary of $172,000.  Additionally, Mr. Fractor is eligible for a discretionary cash bonus.

On April 4, 2011, Mr. Fractor was granted a seven-year option to purchase 42,000 shares of the Company’s common stock at a price of $2.25 per share vesting in equal monthly installments over the three-year term of the agreement. On October 24, 2011, the Company granted Mr. Fractor a seven-year option to purchase 10,000 shares of the Company’s common stock at a price of $1.42 per share vesting in one annual installment of 2,500 shares on October 24, 2012 and in 36 equal monthly installments thereafter. On February 24, 2012, the Company granted Mr. Fractor a seven-year option to purchase 10,000 shares of the Company’s common stock at a price of $1.90 per share vesting over a one-year term ending February 24, 2013. On March 7, 2013, the Company granted Mr. Fractor a seven-year option to purchase 64,000 shares of the Company’s common stock at a price of $2.72 per share vesting in one annual installment of 16,000 shares on March 6, 2014 and in 36 equal monthly installments thereafter.

Summary of Employment Agreements

The aggregate base salary payable pursuant to the above Employment Agreements is approximately $1.0 million.  Additionally during 2013, the Company issued an aggregate of 489,000 stock options to its management group at a weighted average exercise price of $2.66 that vest over a four-year term.

Operating Lease

The Company entered into a lease for new office space effective June 15, 2013 and continuing through August 31, 2016 at an initial monthly rental of $8,063. The monthly rental will increase by 3% on each anniversary date of the lease. Rent for the months of August and September 2013 was abated. Rent expense was approximately $80,000, $55,000 and $40,000 for the years ended December 31, 2013, 2012 and 2011, respectively.

Future minimum rentals under the operating lease are as follows:

Years ending December 31,

Amount

2014

$

97,724

2015

100,905

2016

68,432

Total

$

267,061

Contractual Obligations

The following is a summary of our contractual obligations including those entered into subsequent to December 31, 2013.

Total

Less than

3-Jan

5-Mar

More than

1 year

years

years

5 years

Unconditional purchase obligations for

$

3,212,400

$

1,392,191

$

1,820,209

$

—

$

—

research and development

Operating lease obligation

$

267,061

97,724

169,337

—

—

$

3,479,461

$

1,489,915

$

1,989,546

$

—

$

—

Shareholders_Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2013
Shareholders Equity	'
	6	Shareholders’ Equity
	Common Stock
	In March 2010, the Company raised $1,654,686 (after commissions and offering expenses) from the sale of 1,740,000 shares of common stock and warrants to purchase 696,000 shares of common stock at an exercise price of $1.15 per share, to various investors in a private placement. (See “Warrants and Warrant Liabilities” below.)
	In May 2010, the Company raised $2,716,308 (after commissions and offering expenses) from the sale of 2,490,910 shares of common stock and warrants to purchase 1,245,455 shares of common stock at an exercise price of $1.50 per share, to various investors in a private placement. (See “Warrants and Warrant Liabilities” below)
	In February 2011, the Company raised $7,460,129 (after commissions and offering expenses) from the sale of 5,219,768 shares of common stock and warrants to purchase 2,609,898 shares of common stock at an exercise price of $2.25 per share, to various investors in a private placement. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. The January and October 2012 underwritten public offerings (see below) provided for the issuance of shares at prices that were less than $1.55. Accordingly, the exercise price of these warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,696 net of exercises. (See “Warrants and Warrant Liabilities” below)
	In January 2012, the Company raised $9,271,370 in an underwritten public offering, net of offering expenses of approximately $1.1 million, from the sale of 9,489,436 shares of common stock and warrants to purchase 4,744,718 shares of common stock at an exercise price of $1.41 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.
	In October 2012, the Company raised $19,359,553 in an underwritten public offering, net of offering expenses of approximately $1.6 million, from the sale of 10,000,000 shares of common stock and warrants to purchase 4,500,000 shares of common stock at an exercise price of $2.65 per share, to various investors in an underwritten public offering. The warrants have a term of 60 months from the date of issuance. The warrants do not contain any features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity. Accordingly, the warrants are accounted for as equity.
	Controlled Equity Offering
	On April 18, 2013, the Company entered into a Controlled Equity OfferingSM Sales Agreement (the Sales Agreement) with Cantor Fitzgerald & Co., as agent (Cantor), pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $25.0 million (of which only $17.0 million is currently registered for offer and sale). Under the Sales Agreement, Cantor may sell shares by any method permitted by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as amended, including sales made directly on the NYSE MKT, on any other existing trading market for our common stock or to or through a market maker. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by us from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement. On April 22, 2013, NYSE MKT approved the listing of 10,593,220 shares of our common stock in connection with the Sales Agreement. Through December 31, 2013, we sold 1,862,142 shares of our common stock under the Sales Agreement that resulted in proceeds to the Company of approximately $4,906,078, less offering expenses of approximately $338,000. As of December 31, 2013, aggregate gross sales for additional common stock of approximately $11,754,071 remained available under the Sales Agreement.
	Stock Options
	In February 2005, the Company adopted an Equity Incentive Plan (Plan). Pursuant to the Plan, a committee appointed by the Board of Directors may grant, at its discretion, qualified or nonqualified stock options, stock appreciation rights and may grant or sell restricted stock to key individuals, including employees, nonemployee directors, consultants and advisors. Option prices for qualified incentive stock options (which may only be granted to employees) issued under the plan may not be less than 100% of the fair market value of the common stock on the date the option is granted (unless the option is granted to a person who, at the time of grant, owns more than 10% of the total combined voting power of all classes of stock of the Company; in which case the option price may not be less than 110% of the fair market value of the common stock on the date the option is granted). Option prices for nonqualified stock options issued under the Plan are at the discretion of the committee and may be equal to, greater or less than fair market value of the common stock on the date the option is granted. The options vest over periods determined by the Board of Directors and are exercisable no later than ten years from date of grant (unless they are qualified incentive stock options granted to a person owning more than 10% of the total combined voting power of all classes of stock of the Company, in which case the options are exercisable no later than five years from date of grant). Initially, the Company reserved 6,000,000 shares of common stock for issuance under the Plan. On October 24, 2011, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 8,000,000 shares. On September 20, 2013, the Company’s shareholders voted to increase the number of authorized shares reserved for the Plan to 12,000,000 shares. Options to purchase 3,433,270 common shares have been granted under the Plan and are outstanding as of December 31, 2013.  As of December 31, 2013, there were 5,662,274 options available for issuance under the Plan.
	The following is a summary of stock option grants issued outside the Plan:
	In January 2007, the Company granted an option to purchase 1,500,000 shares of its common stock at an exercise price of $1.10 per share to the Chairman of the Company’s Scientific Advisory Board.
	In November 2006, the Company granted an option to purchase 300,000 shares of its common stock at an exercise price of $1.00 per share to an affiliate of the Company’s then Chairman of the Board.
	In November 2006, the Company granted an option to purchase 5,933,424 shares of its common stock at an exercise price of $1.00 per share to a Board member in connection with the Cedars-Sinai license acquisition.
	The following table summarizes stock option activity for the Company during the three years ended December 31, 2013:
						Weighted			Weighted
						Average			Average			Aggregate
						Exercise			Contractual			Intrinsic
			Options			Price			Term			Value
	Outstanding December 31, 2010			11,094,845		$	0.92			-
	Granted			1,077,000		$	0.91
	Exercised			(1,269,767	)	$	0.39
	Forfeited or expired			(128,000	)	$	1.04
	Outstanding December 31, 2011			10,774,078		$	1.07
	Granted			1,292,500		$	2.5
	Exercised			(1,285,384	)	$	0.95
	Forfeited or expired			(200,000	)	$	2.25
	Outstanding December 31, 2012			10,581,194		$	1.16
	Granted			862,287		$	2.67
	Exercised			(829,702	)	$	0.92
	Forfeited or expired			(147,084	)	$	1.81
	Outstanding December 31, 2013			10,466,695		$	1.37			3.61		$	49,938
				8,710,260		$	2.67			2.76		$	49,938
	Vested or expected to vest at December 31, 2013
	As of December 31, 2013, the total unrecognized compensation cost related to unvested stock options amounted to $4,188,162, which will be amortized over the weighted-average remaining requisite service period of approximately 21 months.
	Warrants
	In connection with the March 2010 common stock private placement, the Company issued to the investors warrants to purchase 696,000 shares of the Company’s common stock at $1.15 per share. The warrants had a term of 26 months from the date of issuance. As of December 31, 2013, these warrants have been fully exercised.
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,245,455 shares of the Company’s common stock at $1.50 per share. The warrants have a term of 36 months from the date of issuance. As of December 31, 2013 these warrants have been fully exercised, except for warrants to purchase 4,000 shares of the Company’s common stock that expired. (see Warrant Liabilities below)
	In connection with the sale of Preferred Stock in May 2010, the Company issued warrants to purchase 1,350,000 shares of common stock at an exercise price of $2.50. The warrants have a term of five-years from the date of issuance. As of December 31, 2013, warrants to purchase 1,290,996 shares of the Company’s common stock at $2.50 were outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. The warrants have a five-year term from the date of issuance and contain a provision that provides for an adjustment to the exercise price in the event the Company completes an equity financing at a per share price of its common stock that is less than the adjusted exercise price. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,670 net of exercises. As of December 31, 2013, warrants to purchase 2,823,670 shares of the Company’s common stock were outstanding related to this private placement. (See “Warrant Liability” below.)
	In connection with the January 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,744,718 shares of the Company’s common stock at $1.41 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of December 31, 2013, warrants to purchase 1,418,575 shares of the Company’s common stock remain outstanding relating to this public offering.
	In connection with the October 2012 underwritten public offering, the Company issued to the investors warrants to purchase 4,500,000 shares of the Company’s common stock at $2.65 per share. The warrants have a five-year term from the date of issuance. These warrants qualify for equity treatment since they do not have any provisions that would require the Company to redeem them for cash or that would result in an adjustment to the number of warrants. As of December 31, 2013, warrants to purchase 4,446,775 shares of the Company’s common stock remain outstanding relating to this public offering.
	Warrant Liability
	The Company’s warrant liability is adjusted to fair value each reporting period and is influenced by several factors including the price of the Company’s common stock as of the balance sheet date. On December 31, 2013, the price per share of Company’s common stock was $0.93 per share compared to $1.92 per share at December 31, 2012 and $1.36 per share at December 31, 2011.
	In connection with the March 2010 common stock private placement, the Company issued to the investors warrants to purchase 696,000 shares of the Company’s common stock at $1.15 per share. Of the total proceeds from the March 2010 common stock private placement, $257,520 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability was adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company had concluded that Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the lattice simulation model, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.00%, and (iv) contractual life of 26 months. During the year ended December 31, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. During 2012, the remaining warrants were fully exercised; however, the Company recorded a charge to other expense of $745,500 as the Company revalued the warrants through the date of exercise.
	In connection with the May 2010 common stock private placement, the Company issued to the investors warrants to purchase 1,245,455 shares of the Company’s common stock at $1.50 per share. Of the total proceeds from the May 2010 common stock private placement, $834,455 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that future common stock issuances are made at a price less than $1.00. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 1.375%, and (iv) contractual life of 36 months. Effective January 1, 2011 the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. The binomial lattice simulation model used by the Company at December 31, 2012, assumed (i) dividend yield of 0%; (ii) expected volatility of 78%; (iii) risk free rate of 0.08% and (iv) expected term of 0.42 years. Based upon this model, the Company recorded a charge to other expense of $357,808 during the year ended December 31, 2012. During 2013, the remaining warrants were fully exercised; however, the Company recorded a charge to other expense of $583,134 as the Company revalued the warrants through the date of exercise.
	In connection with the sale of Preferred Stock in 2010, the Company vested warrants to purchase 1,350,000 shares of the Company’s common stock at an exercise price of $2.50 per share. Of the total proceeds from the May 2010 preferred stock sale, $5,710,500 was allocated to the freestanding warrants associated with the units based upon the fair value of these warrants determined under the Black Scholes option pricing model. The warrants contain a provision whereby the warrant may be settled for cash in connection with a change of control with a private company. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. The warrant liability is adjusted to fair value each reporting period and any change in value is recognized in the statement of operations. Prior to 2011, the Company concluded that the Black-Scholes method of valuing the price adjustment feature does not materially differ from the valuation of such warrants using the Monte Carlo or binomial lattice simulation models, and therefore, the use of the Black-Scholes valuation model was considered a reasonable method to value the warrants. The assumptions used in the Black Scholes model for determining the initial fair value of the warrants were as follows: (i) dividend yield of 0%; (ii) expected volatility of 102%, (iii) risk-free interest rate of 2.50%, and (iv) contractual life of 60 months. Effective January 1, 2011, the Company determined that it was more appropriate to value the warrants using a binomial lattice simulation model. The lattice simulation model used by the Company at December 31, 2012, assumed (i) dividend yield of 0%; (ii) expected volatility of 67%; (iii) risk free rate of 0.30% and (iv) expected term of 2.42 years. Based upon this model, the Company recorded a charge to other expense of $128,344 for the year ended December 31, 2012.  As of December 31, 2013, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 123%; (iii) risk free rate of 0.21% and (iv) expected term of 1.34 years. For the year ended December 31, 2013, the Company recorded a credit to other expense of $320,167. As of December 31, 2013, the carrying value of the warrant liability is $268,528.
	In connection with the February 2011 common stock private placement, the Company issued to the investors warrants to purchase 2,818,675 shares of the Company’s common stock at $2.25 per share. Of the total proceeds from the February 2011 common stock private placement, $2,476,790 was allocated to the freestanding warrants associated with the units based upon the fair value of the warrants determined under the Binomial lattice model. The warrants contain a provision whereby the warrant exercise price would be decreased in the event that certain future common stock issuances are made at a price less than $1.55. Due to the potential variability of their exercise price, these warrants do not qualify for equity treatment, and therefore are recognized as a liability. As a result of the January and October 2012 financings, the exercise price of the warrants was adjusted to $1.87 and the number of warrants was proportionately increased to 2,823,696 net of exercises. The Company recorded a charge to financing expense of $397,294 to reflect the issuance of the additional warrants. The warrant liability is adjusted to fair value each reporting period, and any change in value is recognized in the statement of operations. The Company initially valued these warrants using a binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 146%; (iii) risk free rate of 1.96% and (iv) expected term of 5 years. Based upon those calculations, the Company calculated the initial valuation of the warrants to be $2,476,790. The lattice simulation model used by the Company at December 31, 2012 assumed (i) dividend yield of 0%; (ii) expected volatility of 67%; (iii) risk free rate of 0.39% and (iv) expected term of 3.15 years. For the year ended December 31, 2012, the Company recorded a charge to other expense of $1,048,271. As of December 31, 2013, the Company revalued the warrants using the binomial lattice simulation model assuming (i) dividend yield of 0%; (ii) expected volatility of 111%; (iii) risk free rate of 0.44% and (iv) expected term of 2.14 years. For the year ended December 31, 2013, the Company recorded a credit to other expense of $905,377. As of December 31, 2013, the carrying value of the warrant liability is $796,282.
	The below table summarizes the warrant liability activity for the years ended December 31, 2013, 2011 and 2010. The loss included in earnings is reflective of several factors including the increase in the Company’s stock during the years ended December 31, 2013, 2011 and 2010.
			2013			2012			2011
	Beginning Balance, January 1		$	2,852,880		$	2,157,408		$	2,581,871
	Issuance of warrants and effect of repricing			—			397,294			—
	Exercise of warrants			(1,145,659	)		(1,981,745	)		2,476,790
	(Gain) or loss included in earnings			(642,411	)		2,279,923			(2,901,253	)
	Transfers in and/or out of Level 3			—			—			—
	Ending Balance, December 31		$	1,064,810		$	2,852,880		$	2,157,408

401K_Profit_Sharing_Plan

401(K) Profit Sharing Plan	12 Months Ended
	Dec. 31, 2013
401(k) Profit Sharing Plan	'
	7	401(k) Profit Sharing Plan
	During 2011, the Company adopted a Profit Sharing Plan that qualifies under Section 401(k) of the Internal Revenue Code. Contributions to the plan are at the Company’s discretion. The Company did not make any matching contributions during the years ended December 31, 2013 and 2012.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Taxes	'
	8	Income Taxes
	Deferred taxes represent the net tax effects of the temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes. Temporary differences result primarily from the recording of tax benefits of net operating loss carry forwards and stock-based compensation.
	As of December 31, 2013, the Company has an insufficient history to support the likelihood of ultimate realization of the benefit associated with the deferred tax asset. Accordingly, a valuation allowance has been established for the full amount of the net deferred tax asset.
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
			2013			2012			2011
	Income tax benefit at the federal statutory rate			-34	%		-34	%		-34	%
	State income tax benefit, net of federal tax benefit			-6	%		-6	%		-6	%
	Change in fair value of warrant liability			-3	%		-6	%		20	%
	Change in valuation allowance for deferred tax assets			43	%		46	%		20	%
	Total			0	%		0	%		0	%
	Deferred taxes consisted of the following:
			December 31,			December 31,
			2013			2012
	Net operating loss carryforwards		$	15,759,274		$	12,821,749
	Stock-based compensation			2,020,987			1,796,954
	Less valuation allowance			(17,780,261	)		(14,618,703	)
	Net deferred tax asset		$	—		$	—
	As of December 31, 2013, the Company had federal and California income tax net operating loss carryforwards of approximately $40.8 million. These net operating losses will begin to expire in 2022 and 2016, respectively, unless previously utilized.
	Section 382 of the Internal Revenue Code can limit the amount of net operating losses which may be utilized if certain changes to a company’s ownership occur. While the Company underwent an ownership change in 2012 as defined by Section 382 of the Internal Revenue Code, management estimated that the Company has not incurred any limitations on its ability to utilize its net operating losses under Section 382 of the Internal Revenue Code during 2013. The Company may incur limitations in the future if there are additional changes in ownership.

Supplementary_Financial_Inform

Supplementary Financial Information	12 Months Ended
	Dec. 31, 2013
Supplementary Financial Information	'
	9	Supplementary Financial Information
	Summary of Quarterly Results (Unaudited)
			Quarter Ended
			March			June			September			December			Fiscal Year
	Fiscal 2013
	Revenues		$	—		$	—		$	—		$	—		$	—
	Net income (loss)			(4,973,791	)		(150,329	)		(3,793,441	)		116,998			(8,800,563	)
	Net income (loss) per common share
	Basic		$	(0.10	)	$	(0.00	)	$	(0.07	)	$	(0.00	)	$	(0.16	)
	Diluted		$	(0.10	)	$	(0.00	)	$	(0.07	)	$	(0.00	)	$	(0.16	)
	Fiscal 2012
	Revenues		$	—		$	—		$	—		$	—		$	—
	Net income (loss)			(7,889,435	)		(6,451,817	)		(637,627	)		483,740			(14,495,139	)
	Net income (loss) per common share
	Basic		$	(0.21	)	$	(0.16	)	$	(0.02	)	$	0.01		$	(0.35	)
	Diluted		$	(0.21	)	$	(0.16	)	$	(0.02	)	$	0.01		$	(0.35	)

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Subsequent Events	'
	10	Subsequent Events
	Warrant Exercises
	Subsequent to December 31, 2013, the Company issued 23,473 shares of common stock upon the cashless exercise of options to purchase 75,000 shares of common stock.
	Stock Option Grants
	The Company’s Board of Directors approved the granting of 330,000 stock options to certain officers and employees on March 7, 2014. These options have an exercise price equal to the closing stock price on March 7, 2014 of $1.34 and will vest over a period of four years.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2013
Valuation and Qualifying Accounts	'
	IMMUNOCELLULAR THERAPEUTICS, LTD.
	Schedule II - Valuation and Qualifying Accounts
		Additions
		Beginning		Charged to		Other	Deductions	Ending
		Balance		Costs &		Amounts		Balance
				Expenses
	2013
	Deferred Tax Asset Valuation Account	$	14,618,703	$	3,161,558			$	17,780,261
	2012
	Deferred Tax Asset Valuation Account	$	11,004,790	$	3,613,913			$	14,618,703
	2011
	Deferred Tax Asset Valuation Account	$	7,429,620	$	3,575,170			$	11,004,790

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Development Stage Enterprise	'
	Development Stage Enterprise—The Company is a development stage enterprise and is devoting substantially all our present efforts to research and development. All losses accumulated since inception are considered part of the Company’s development stage activities.
Liquidity	'
	Liquidity —As of December 31, 2013, the Company had working capital of $27,007,377, compared to working capital of $25,832,869 as of December 31, 2012. The estimated cost of completing the development of any of our current vaccine product candidates and of obtaining all required regulatory approvals to market any of those product candidates is substantially greater than the amount of funds we currently have available. However, we believe that our existing cash balances are sufficient for our currently planned level of operations for at least the next twelve months, although there is no assurance that such proceeds will be sufficient for this purpose.
Cash and cash equivalents	'
	Cash and cash equivalents—The Company considers all highly liquid instruments with an original maturity of 90 days or less to be cash equivalents. As of December 31, 2013 and December 31, 2012, the Company had $25,913,893 and $23,646,922, respectively, of certificates of deposit. The Company places its cash and cash equivalents with various banks in order to maintain FDIC insurance on all of its investments..
Property and Equipment	'
	Property and Equipment—Property and equipment are stated at cost and depreciated using the straight-line methods based on the estimated useful lives (generally three to five years) of the related assets. Computer and computer equipment are depreciated over three years. Management continuously monitors and evaluates the realizability of recorded long-lived assets to determine whether their carrying values have been impaired. The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the nondiscounted cash flows estimated to be generated by those assets are less than the carrying amount of those assets. Any impairment loss is measured by comparing the fair value of the asset to its carrying amount. Repairs and maintenance costs are expensed as incurred.
Research and Development Expenses	'
	Research and Development Expenses—Research and development expenses consist of costs incurred for direct research and development and are expensed as incurred
Stock Based Compensation	'
	Stock Based Compensation—The Company records the cost for all share-based payment transactions in the Company’s financial statements.
	Stock option grants issued prior to March 31, 2011 to employees and officers and directors were valued using the Black-Scholes pricing model. Stock option grants made subsequent to March 31, 2011 were valued using the binomial lattice simulation model.
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Year			Year			Year
		Ended			Ended			Ended
		December 31,			December 31,			December 31,
		2013			2012			2011
	Risk-free interest rate		1.64	%		0.49	%		1.89	%
	Expected dividend yield		None			None			None
	Expected life		5.21 years			4.40 years			5.8 years
	Expected volatility		90.58	%		66.1	%		64	%
	Expected forfeitures		0	%		0	%		0	%
	The weighted-average grant-date fair value of options granted during the year ended December 31, 2013, 2012 and 2011 was $1.89, $1.29 and $0.98, respectively.
	The risk-free interest rate used is based on the implied yield currently available in U.S. Treasury securities at maturity with an equivalent term. The Company has not declared or paid any dividends and does not currently expect to do so in the future. The expected term of options represents the period that our stock-based awards are expected to be outstanding and was determined based on projected holding periods for the remaining unexercised shares. Consideration was given to the contractual terms of our stock-based awards, vesting schedules and expectations of future employee behavior. For the year ended December 31, 2013, the expected volatility is based upon the historical volatility of the Company’s common stock. Forfeitures have been estimated to be nil.
	The Company’s stock price volatility and option lives involve management’s best estimates, both of which impact the fair value of the option calculated and, ultimately, the expense that will be recognized over the life of the option.
	When options are exercised, our policy is to issue previously unissued shares of common stock to satisfy share option exercises. As of December 31, 2013, the Company had 56,617,707 shares of authorized but unissued common stock.
	No tax benefits were attributed to the stock-based compensation expense because a valuation allowance was maintained for all net deferred tax assets.
Income Taxes	'
	Income Taxes—The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. As of December 31, 2013 and 2012, the Company fully reserved its deferred tax assets. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. As of December 31, 2013, the Company had no unrecognized tax benefits and as such, no liability, interest or penalties were required to be recorded.  The Company does not expect this to change significantly in the next twelve months.  The Company has determined that its main taxing jurisdictions are the United States of America and the State of California.  The Company is not currently under examination by any taxing authority nor has it been notified of a pending examination. The Company’s tax returns are generally no longer subject to examination for the years before December 31, 2009 for the state and December 31, 2010 for the federal taxing authority.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments—The carrying amounts reported in the balance sheets for cash, cash equivalents, and accounts payable approximate their fair values due to their quick turnover. The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.
	Fair value for financial reporting is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.  The Company utilizes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:
	Level 1 - quoted prices in active markets for identical assets or liabilities
	Level 2 - quoted prices for similar assets and liabilities in active markets or inputs that are observable
	Level 3 - inputs that are unobservable (for example cash flow modeling inputs based on assumptions)
	Warrant liabilities represent the only financial assets or liabilities recorded at fair value by the Company. The fair value of warrant liabilities are determined based on Level 3 inputs.
Use of Estimates	'
	Use of Estimates—The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these financial statements.
Basic and Diluted Net Loss per Common Share	'
	Basic and Diluted Net Loss per Common Share—Basic and diluted net loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents (which consist of options and warrants) are excluded from the computation of diluted net loss per share for the years ended December 31, 2013, 2012 and 2011, since the effect would be antidilutive. Common share equivalents which could potentially dilute basic earnings per share in the future, and which were excluded from the computation of diluted net loss per share, totaled 26,108,984, 24,139,760 and 17,405,930 shares at December 31, 2013, 2012 and 2011, respectively.
Recently Issued Accounting Standards	'
	Recently Issued Accounting Standards— In June 2011, the Financial Accounting Standards Board (FASB) issued ASU No. 2011-5, which amends the Comprehensive Income Topic of the ASC. The ASU eliminates the option to present the components of other comprehensive income as part of the statement of changes in shareholders’ equity, and instead requires consecutive presentation of the statement of net income and other comprehensive income either in a continuous statement of comprehensive income or in two separate but consecutive statements. ASU No. 2011-5 became effective for interim and annual periods beginning after December 15, 2011. In February 2013, the FASB issued ASU No. 2013-02, which further amends the Comprehensive Income Topic of the ASC. This amendment requires entities to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount is being reclassified in its entirety to net income. This standard became effective for periods beginning after December 15, 2012. The adoption of these ASU’s did not have a material impact on the Company’s results of operations, financial condition or liquidity.
	Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities Exchange Commission (the SEC) did not or are not believed by management to have a material impact on the Company’s present or future condensed financial statements.
Critical Accounting Policies	'
Stock Based Compensation	'
	Stock-Based Compensation - Stock-based compensation expense is estimated as of the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which generally equals the vesting period, based on the number of awards that are expected to vest. Estimating the fair value for stock options requires judgment, including the expected term of our stock options, volatility of the company’s stock, expected dividends, risk-free interest rates over the expected term of the options and the expected forfeiture rate. In connection with performance based programs, the company makes assumptions principally related to the number of awards that are expected to vest after assessing the probability that certain performance criteria will be met.
Income Taxes	'
	Income Taxes - The Company accounts for federal and state income taxes under the liability method, with a deferred tax asset or liability determined based on the difference between the financial statement and tax basis of assets and liabilities, as measured by the enacted tax rates. The Company’s provision for income taxes represents the amount of taxes currently payable, if any, plus the change in the amount of net deferred tax assets or liabilities. A valuation allowance is provided against net deferred tax assets if recoverability is uncertain on a more likely than not basis. The Company recognizes in its financial statements the impact of an uncertain tax position if the position will more likely than not be sustained upon examination by a taxing authority, based on the technical merits of the position. The Company’s policy is to recognize interest related to unrecognized tax benefits as interest expense and penalties as operating expenses. The Company is not currently under examination by any taxing authority nor has it been notified of an impending examination. The Company’s tax returns for the years ended December 31, 2013, 2012 and 2011, remain open for possible review.
Warrant Liability	'
	Warrant liability - The fair value of warrant liability is estimated using the Binomial Lattice option valuation model.  The use of the Binomial Lattice option valuation model requires estimates including the volatility of the company’s stock, risk-free rates over the expected term of warrants and early exercise of the options.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Stock Options Grants	'
	Fair value was estimated at the date of grant using the following weighted average assumptions:
		Year			Year			Year
		Ended			Ended			Ended
		December 31,			December 31,			December 31,
		2013			2012			2011
	Risk-free interest rate		1.64	%		0.49	%		1.89	%
	Expected dividend yield		None			None			None
	Expected life		5.21 years			4.40 years			5.8 years
	Expected volatility		90.58	%		66.1	%		64	%
	Expected forfeitures		0	%		0	%		0	%

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Components of Property and Equipment	'
	Property and equipment consist of the following:
		December 31,			December 31,
		2013			2012
	Computers	$	67,566		$	23,192
	Research equipment		117,809			128,381
			185,375			151,573
	Accumulated depreciation		(118,933	)		(75,284	)
		$	66,442		$	76,289

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2013
Future Minimum Rentals Under Operating Lease	'
	Future minimum rentals under the operating lease are as follows:
	Years ending December 31,	Amount
	2014	$	97,724
	2015		100,905
	2016		68,432
	Total	$	267,061
Summary of Contractual Obligations	'
		Total		Less than		3-Jan		5-Mar		More than
				1 year		years		years		5 years
	Unconditional purchase obligations for	$	3,212,400	$	1,392,191	$	1,820,209	$	—	$	—
	research and development
	Operating lease obligation	$	267,061		97,724		169,337		—		—
		$	3,479,461	$	1,489,915	$	1,989,546	$	—	$	—

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Stock Options Activity	'
	The following table summarizes stock option activity for the Company during the three years ended December 31, 2013:
					Weighted			Weighted
					Average			Average			Aggregate
					Exercise			Contractual			Intrinsic
		Options			Price			Term			Value
	Outstanding December 31, 2010		11,094,845		$	0.92			-
	Granted		1,077,000		$	0.91
	Exercised		(1,269,767	)	$	0.39
	Forfeited or expired		(128,000	)	$	1.04
	Outstanding December 31, 2011		10,774,078		$	1.07
	Granted		1,292,500		$	2.5
	Exercised		(1,285,384	)	$	0.95
	Forfeited or expired		(200,000	)	$	2.25
	Outstanding December 31, 2012		10,581,194		$	1.16
	Granted		862,287		$	2.67
	Exercised		(829,702	)	$	0.92
	Forfeited or expired		(147,084	)	$	1.81
	Outstanding December 31, 2013		10,466,695		$	1.37			3.61		$	49,938
			8,710,260		$	2.67			2.76		$	49,938
	Vested or expected to vest at December 31, 2013
Summary of Carrying Value of Warrant Liability	'
	The below table summarizes the warrant liability activity for the years ended December 31, 2013, 2011 and 2010. The loss included in earnings is reflective of several factors including the increase in the Company’s stock during the years ended December 31, 2013, 2011 and 2010.
		2013			2012			2011
	Beginning Balance, January 1	$	2,852,880		$	2,157,408		$	2,581,871
	Issuance of warrants and effect of repricing		—			397,294			—
	Exercise of warrants		(1,145,659	)		(1,981,745	)		2,476,790
	(Gain) or loss included in earnings		(642,411	)		2,279,923			(2,901,253	)
	Transfers in and/or out of Level 3		—			—			—
	Ending Balance, December 31	$	1,064,810		$	2,852,880		$	2,157,408

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Federal Statutory Income Tax Rate to Loss before Income Taxes	'
	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows:
		2013			2012			2011
	Income tax benefit at the federal statutory rate		-34	%		-34	%		-34	%
	State income tax benefit, net of federal tax benefit		-6	%		-6	%		-6	%
	Change in fair value of warrant liability		-3	%		-6	%		20	%
	Change in valuation allowance for deferred tax assets		43	%		46	%		20	%
	Total		0	%		0	%		0	%
Deferred Tax Asset	'
	Deferred taxes consisted of the following:
		December 31,			December 31,
		2013			2012
	Net operating loss carryforwards	$	15,759,274		$	12,821,749
	Stock-based compensation		2,020,987			1,796,954
	Less valuation allowance		(17,780,261	)		(14,618,703	)
	Net deferred tax asset	$	—		$	—

Supplementary_Financial_Inform1

Supplementary Financial Information (Tables)	12 Months Ended
	Dec. 31, 2013
Summary of Quarterly Results (Unaudited)	'
		Quarter Ended
		March			June			September			December			Fiscal Year
	Fiscal 2013
	Revenues	$	—		$	—		$	—		$	—		$	—
	Net income (loss)		(4,973,791	)		(150,329	)		(3,793,441	)		116,998			(8,800,563	)
	Net income (loss) per common share
	Basic	$	(0.10	)	$	(0.00	)	$	(0.07	)	$	(0.00	)	$	(0.16	)
	Diluted	$	(0.10	)	$	(0.00	)	$	(0.07	)	$	(0.00	)	$	(0.16	)
	Fiscal 2012
	Revenues	$	—		$	—		$	—		$	—		$	—
	Net income (loss)		(7,889,435	)		(6,451,817	)		(637,627	)		483,740			(14,495,139	)
	Net income (loss) per common share
	Basic	$	(0.21	)	$	(0.16	)	$	(0.02	)	$	0.01		$	(0.35	)
	Diluted	$	(0.21	)	$	(0.16	)	$	(0.02	)	$	0.01		$	(0.35	)

Nature_of_Organization_and_Dev1

Nature of Organization and Development Stage Operations (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Nature Of Organization And Development Stage Operations (Textual) [Abstract]	'	'
Deficit accumulated during the development stage	$51,969,393	$43,168,830

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Schedule of stock options grants	'	'	'
Risk-free interest rate	1.64%	0.49%	1.89%
Expected dividend yield	0.00%	0.00%	0.00%
Expected life	'5 years 2 months 16 days	'4 years 4 months 24 days	'5 years 9 months 18 days
Expected volatility	90.58%	66.10%	64.00%
Expected forfeitures	0.00%	0.00%	0.00%

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Additional Information (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary Of Significant Accounting Policies (Additional Textual) [Abstract]	'	'	'
Working capital	$27,007,377	$25,832,869	'
Original maturity of highly liquid instruments	'90 days	'	'
Certificates of deposit	25,913,893	23,646,922	'
Estimated useful lives of property and equipment	'generally three to five years	'	'
Shares authorized but unissued common stock	56,617,707	'	'
Weighted-average grant-date fair value of options granted	$1.89	$1.29	$0.98
Tax benefit attributed to the stock-based compensation expense	$0	$0	$0
Shares excluded from the computation of diluted net loss per share	26,108,984	24,139,760	17,405,930
Computer Equipment	'	'	'
Summary of Significant Accounting Policies (Textual) [Abstract]	'	'	'
Computer and computer equipment depreciation period	'3 years	'	'

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Components of Property and Equipment	'	'
Property and equipment, gross	$185,375	$151,573
Accumulated depreciation	-118,933	-75,284
Property and equipment, net	66,442	76,289
Computer Equipment	'	'
Components of Property and Equipment	'	'
Property and equipment, gross	67,566	23,192
Research Equipment	'	'
Components of Property and Equipment	'	'
Property and equipment, gross	$117,809	$128,381

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Details) (USD $)	12 Months Ended			118 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Property and Equipment (Textual) [Abstract]	'	'	'	'
Depreciation expense	$50,402	$45,823	$20,357	$125,687

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	1 Months Ended	12 Months Ended							12 Months Ended
	Nov. 30, 2006	Sep. 19, 2013	Sep. 20, 2010	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Jun. 16, 2008	Sep. 20, 2011	Sep. 20, 2012
									Amendment No. 1	Amendment No. 2
Related Party Transactions (Textual) [Abstract]	'	'	'	'	'	'	'	'	'	'
Common stock, shares issued	694,000	'	'	'	'	'	'	'	'	'
Payment for upfront licensing fee	$62,000	'	'	'	'	'	'	'	'	'
Funding from equity	'	'	'	'	'	'	5,000,000	'	'	'
Payment to related Party	'	'	'	'	'	166,660	'	'	'	'
Shares issued to related parties	'	'	'	'	'	'	'	100,000	'	'
Other funding to related parties	'	'	'	5,000,000	2,500,000	'	'	'	'	'
Expected final contract price	'	$210,856	$446,142	'	'	'	'	'	$294,504	$329,832

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2013
Future Minimum Rentals Under the Operating Lease	'
2014	$97,724
2015	100,905
2016	68,432
Operating lease obligation total	$267,061

Commitments_and_Contingencies_2

Commitments and Contingencies (Details 1) (USD $)	Dec. 31, 2013
Summary of contractual obligations	'
Unconditional purchase obligations for research and development total	$3,212,400
Unconditional purchase obligations for research and development less than one year	1,392,191
Unconditional purchase obligations for research and development one to three years	1,820,209
Unconditional purchase obligations for research and development three to five years	0
Unconditional purchase obligations for research and development more than five years	0
Operating lease obligation total	267,061
Operating lease obligation less than year	97,724
Operating lease obligation one to three years	169,337
Operating lease obligation three to five years	0
Operating lease obligation more than five years	0
Total	3,479,461
less than one year	1,489,915
One to three years	1,989,546
Three to five years	0
More than five years	$0

Commitments_and_Contingencies_3

Commitments and Contingencies - Additional Information (Details) (USD $)

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Jan. 11, 2013

Feb. 29, 2012

Jan. 20, 2011

Dec. 31, 2013

Sep. 17, 2013

Mar. 31, 2012

Dec. 31, 2012

Mar. 31, 2012

31-May-11

31-May-11

Jun. 30, 2013

Sep. 30, 2013

Aug. 31, 2013

Sep. 30, 2013

Mar. 31, 2013

Feb. 29, 2012

Oct. 31, 2011

Apr. 30, 2011

Dec. 31, 2013

Mar. 31, 2013

Feb. 29, 2012

Oct. 31, 2011

Apr. 30, 2011

Dec. 31, 2013

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Aptiv Solution

Agreement with Andrew Gengos

Agreement with Andrew Gengos

Agreement with Andrew Gengos

Agreement with Dr. John Yu

Agreement with Dr. John Yu

Agreement with Dr. John Yu

Agreement with Anthony Gringeri

Agreement with Anthony Gringeri

Agreement with Anthony Gringeri

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

Employment Agreement with David Fractor

ContractAmendments

AnnualInstallments

Seven Year Incentive Stock Option

Seven Year Incentive Stock Option

Five Year Incentive Stock Option

AnnualInstallments

Ten Year Incentive Stock Option

AnnualInstallments

AnnualInstallments

MonthlyInstallments

MonthlyInstallments

Seven Year Incentive Stock Option

Seven Year Incentive Stock Option

Seven Year Incentive Stock Option

Seven Year Incentive Stock Option

Seven Year Incentive Stock Option

MonthlyInstallments

AnnualInstallments

AnnualInstallments

MonthlyInstallments

AnnualInstallments

Commitments And Contingencies Textual [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for services

'

'

'

'

'

'

$3,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of contract amendments

'

'

'

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amendment additional fee

'

'

'

608,201

986,783

469,807

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Extended agreement date

31-Mar-14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total aggregate fee

'

'

'

'

'

'

5,078,169

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated payments for services

'

'

'

'

'

'

'

2,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Company's remaining commitment obligation

'

'

'

'

'

'

3,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Period within effective date of License Agreement

'30 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Nonrefundable And Noncreditable License And Maintenance Fee

'12 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Base salary

'

'

'

'

'

'

'

'

400,000

'

'

125,000

'

'

'

310,000

'

'

'

'

172,000

1,000,000

'

'

'

'

'

Annual discretionary bonus of base annual salary

'

'

'

'

'

'

'

'

40.00%

'

'

'

'

'

'

30.00%

'

'

'

'

'

'

'

'

'

'

'

Purchase of stock option

862,287

1,292,500

1,077,000

'

'

'

'

'

'

'

700,000

'

50,000

45,000

'

'

300,000

'

'

'

'

489,000

64,000

10,000

10,000

42,000

16,000

Exercise option price

$2.67

$2.50

$0.91

'

'

'

'

'

'

'

$2.13

'

$1.95

$2.19

'

'

$2.70

'

'

'

'

$2.66

$2.72

$1.90

$1.42

$2.25

'

Number of monthly installments for options to vest

'

'

'

'

'

'

'

'

36

'

'

'

'

'

36

'

'

'

'

36

'

36

'

'

'

'

'

Number of annual installments for options to vest

'

'

'

'

'

'

'

'

1

'

'

'

3

4

1

'

'

1

1

1

'

'

'

'

'

'

'

Options, Vesting in installments

'

'

'

'

'

'

'

'

'

175,000

'

'

'

'

75,000

'

'

'

'

2,500

'

'

'

'

'

'

'

Period of service to be provided after termination

'

'

'

'

'

'

'

'

'90 days

'

'

'12 months

'

'

'90 days

'

'

'

'

'

'

'

'

'

'

'

'

Exercise within term of the option

'

'

'

'

'

'

'

'

'7 years

'

'

'

'7 years

'5 years

'10 years

'

'

'

'

'

'7 years

'4 years

'

'

'

'

'

Amount paid by company for terminating employment agreement without cause

'

'

'

'

'

'

'

'

'one-year of Mr. Gengosb base salary

'

'

'

'

'

'six months of Dr. Gringeribs base salary

'

'

'

'

'

'

'

'

'

'

'

'

Period of premium to be paid

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'6 months

'

'

'

'

'

'

'

'

'

'

'

'

Employment agreement termination notice period

'

'

'

'

'

'

'

'

'

'

'

'60 days

'

'

'

'

'

'

'

'

'30 days

'

'

'

'

'

'

Term of employment agreement renewal

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of employment agreement termination

'

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Term of employment agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

Period of monthly installments for options to vest

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

Lease monthly rent

8,063

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Operating lease rent expense

$80,000

$55,000

$40,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of annual increase of monthly base rent

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of stock option activity	'	'	'
Options outstanding, Beginning Balance	10,581,194	10,774,078	11,094,845
Options, Granted	862,287	1,292,500	1,077,000
Options, Exercised	-829,702	-1,285,384	-1,269,767
Options, Forfeited or expired	-147,084	-200,000	-128,000
Options Outstanding, Ending Balance	10,466,695	10,581,194	10,774,078
Options, Vested or expected to vest	8,710,260	'	'
Weighted Average Exercise Price, Outstanding, Beginning Balance	$1.16	$1.07	$0.92
Weighted Average Exercise Price, Granted	$2.67	$2.50	$0.91
Weighted Average Exercise Price, Exercised	$0.92	$0.95	$0.39
Weighted Average Exercise Price, Forfeited or expired	$1.81	$2.25	$1.04
Weighted Average Exercise Price, Outstanding, Ending Balance	$1.37	$1.16	$1.07
Weighted Average Exercise Price, Vested or expected to vest	$2.67	'	'
Weighted Average Contractual Term, Outstanding	'3 years 7 months 10 days	'	'
Weighted Average Contractual Term, Vested or expected to vest	'2 years 9 months 4 days	'	'
Aggregate Intrinsic Value, Outstanding	$49,938	'	'
Aggregate Intrinsic Value, Vested or expected to vest	$49,938	'	'

Shareholders_Equity_Details_1

Shareholders' Equity (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Summary of carrying value of warrant liability	'	'	'
Beginning Balance, January 1	$2,852,880	$2,157,408	$2,581,871
Issuance of warrants and effect of repricing	'	397,294	'
Exercise of warrants	-1,145,659	-1,981,745	2,476,790
(Gain) or loss included in earnings	-642,411	2,279,923	-2,901,253
Transfers in and/or out of Level 3	'	'	'
Ending Balance, December 31	$1,064,810	$2,852,880	$2,157,408

Shareholders_Equity_Details_Te

Shareholders' Equity (Details Textual) (USD $)

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

Apr. 22, 2013

Apr. 18, 2013

Oct. 31, 2012

Jan. 31, 2012

Feb. 28, 2011

31-May-10

Mar. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Oct. 24, 2011

Feb. 28, 2005

Jan. 31, 2007

Nov. 30, 2006

Nov. 30, 2006

Dec. 31, 2013

Oct. 24, 2011

Dec. 31, 2013

Apr. 18, 2013

Apr. 18, 2013

Feb. 28, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Feb. 28, 2011

Dec. 31, 2011

31-May-10

Dec. 31, 2010

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Oct. 31, 2012

Dec. 31, 2013

Mar. 31, 2010

Dec. 31, 2012

Oct. 31, 2012

Feb. 28, 2011

Oct. 31, 2012

Jan. 31, 2012

Mar. 31, 2010

Dec. 31, 2010

31-May-10

Feb. 28, 2011

31-May-10

Mar. 31, 2010

31-May-13

31-May-10

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2010

31-May-10

31-May-10

Chairman Of Companys Scientific Advisory Board

Affiliate Of Chairman

Board

Stock Compensation Plan

Stock Compensation Plan

Cantor Fitzgerald & Co.

Cantor Fitzgerald & Co.

Cantor Fitzgerald & Co.

February

February

February

February

February

February

February

February

May

May

May

May

January

October

October

March

March

Maximum

Maximum

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Warrant

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Preferred Stock

Warranty Obligations

Warranty Obligations

Offer and sale

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Simulation

Binomial Simulation

Binomial Simulation

Binomial Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

February

February

May

May

May

May

May

May

May

May

May

May

Previous Valuation Assumptions

Previous Valuation Assumptions

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Lattice Simulation

Binomial Simulation

Shareholders' Equity Textual [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the common stock private placement

'

'

$19,359,553

$9,271,370

$7,460,129

$2,716,308

$1,654,686

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,476,790

'

'

'

'

'

'

'

$834,455

'

'

'

'

'

'

$257,520

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sale of common stock and warrants , shares

'

'

10,000,000

9,489,436

5,219,768

2,490,910

1,740,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise option price

'

'

'

'

'

'

'

$2.67

$2.50

$0.91

'

'

'

$1.10

$1

$1

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.55

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of warrants outstanding increased net of exercises

'

'

2,823,670

2,823,696

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercise term investor relations agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'60 months

'60 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Public offering expenses

'

'

1,600,000

1,100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

$2.65

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.65

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock aggregate offering price

'

'

'

'

'

'

'

5,754

5,150

'

'

'

'

'

'

'

'

'

'

25,000,000

17,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Commission rate

'

3.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Listing of shares of common stock in connection with Sales Agreement

10,593,220

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for cash, shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,862,142

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,906,078

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional common stock sales gross

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

11,754,071

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs

'

'

'

'

'

'

'

338,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of fair market value of common stock

'

'

'

'

'

'

'

'not be less than 100%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of common stock voting rights held

'

'

'

'

'

'

'

'more than 10%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum percentage of fair market value of common stock

'

'

'

'

'

'

'

'less than 110%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum exercisable period of options

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum exercisable period of options if percentage of common stock voting rights held is more than ten percent

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares authorized under the plan

'

'

'

'

'

'

'

12,000,000

'

'

'

8,000,000

6,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, shares granted and outstanding

'

'

'

'

'

'

'

10,466,695

10,581,194

10,774,078

11,094,845

'

'

'

'

'

3,433,270

3,433,270

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock options available for issuance

'

'

'

'

'

'

'

5,662,274

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Purchase of common stock, shares

'

'

'

4,744,718

'

'

'

'

'

'

'

'

'

1,500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

696,000

'

'

2,818,675

1,245,455

696,000

'

1,350,000

'

'

'

'

'

'

1,245,455

Options, Granted

'

'

'

'

'

'

'

862,287

1,292,500

1,077,000

'

'

'

'

300,000

5,933,424

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost related to unvested stock options

'

'

'

'

'

'

'

4,188,162

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Weighted-average remaining requisite service period

'

'

'

'

'

'

'

'21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock, price per share

'

'

'

$1.41

'

'

'

$0.93

$1.92

$1.36

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.15

'

'

$2.25

$1.50

$1.15

'

$2.50

$2.50

'

'

'

'

'

$1.50

Warrant Exercise Term Private Placement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

'

'

'

'26 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,000

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock Shares Purchased Private Placement Warrant

'

'

2,823,696

'

'

'

'

2,823,670

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,418,575

'

4,446,775

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,290,996

'

'

'

'

'

'

Warrants exercisable period after initial issuance

'

'

'

'5 years

'5 years

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Adjusted exercise price of warrants

'

'

$1.87

$1.87

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Future common stock issuance price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'less than $1.55

'

'

'price less than $1.00

'

'

'

'

'

'

'

'

'

'

'

'

'less than $1.00

'

Dividend yield rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.00%

0.00%

'

'

'

0.00%

'

0.00%

'

0.00%

'

'

'

'

'

'

'

'

'

'

0.00%

'

'

'

'

'

'

'

'

0.00%

0.00%

0.00%

'

'

Expected volatility rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

111.00%

67.00%

'

'

'

146.00%

'

102.00%

'

78.00%

'

'

'

'

'

'

'

'

'

'

102.00%

'

'

'

'

'

'

'

'

123.00%

67.00%

102.00%

'

'

Risk-free interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.44%

0.39%

'

'

'

1.96%

'

1.38%

'

0.08%

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

'

0.21%

0.30%

2.50%

'

'

Contractual life

'

'

'

'

'

'

'

'

'

'

'26 months

'

'

'

'

'

'

'

'

'

'

'

'

'2 years 1 month 21 days

'3 years 1 month 24 days

'

'

'

'5 years

'

'36 months

'

'5 months 1 day

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'1 year 4 months 2 days

'2 years 5 months 1 day

'60 months

'

'

Change in fair value of warrant liability credited to other income

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

745,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Charge to other expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,048,271

'

'

'

'

583,134

357,808

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

128,344

'

'

'

Proceeds from warrant shares attributed to free standing warrants related party of investor

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,710,500

'

'

'

'

'

'

'

'

Warrant liability carrying value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

796,282

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

268,528

'

'

'

'

'

'

Credit to other expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

905,377

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

320,167

'

'

'

'

'

Charge to financing expense

'

'

'

'

'

'

'

'

397,294

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial valuation of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,476,790

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

401k_Profit_Sharing_Plan_Detai

401(k) Profit Sharing Plan (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
401(k) Profit Sharing Plan (Textual) [Abstract]	'	'
Discretionary cash bonus	$0	$0

Income_Taxes_Details

Income Taxes (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Federal statutory income tax rate to loss before income taxes	'	'	'
Income tax benefit at the federal statutory rate	-34.00%	-34.00%	-34.00%
State income tax benefit, net of federal tax benefit	-6.00%	-6.00%	-6.00%
Change in fair value of warrant liability	-3.00%	-6.00%	20.00%
Change in valuation allowance for deferred tax assets	43.00%	46.00%	20.00%
Total	0.00%	0.00%	0.00%

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Tax Asset	'	'
Net operating loss carryforwards	$15,759,274	$12,821,749
Stock-based compensation	2,020,987	1,796,954
Less valuation allowance	-17,780,261	-14,618,703
Net deferred tax asset	'	'

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013
Income Taxes (Additional Textual) [Abstract]	'
Net operating losses expiration date	'expire in 2022 and 2016
Federal	'
Income Taxes (Additional Textual) [Abstract]	'
Income tax net operating loss carryforwards	40.8
California	'
Income Taxes (Additional Textual) [Abstract]	'
Income tax net operating loss carryforwards	40.8

Supplementary_Financial_Inform2

Supplementary Financial Information (Details) (USD $)

3 Months Ended

10 Months Ended

12 Months Ended

118 Months Ended

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Dec. 31, 2004

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2006

Dec. 31, 2005

Dec. 31, 2013

Summary of Quarterly Results (Unaudited)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$300,000

Net income (loss)

$116,998

($3,793,441)

($150,329)

($4,973,791)

$483,740

($637,627)

($6,451,817)

($7,889,435)

($11,741)

($8,800,563)

($14,495,139)

($5,719,903)

($6,150,142)

($2,626,205)

($3,059,730)

($3,614,753)

($5,152,713)

($246,004)

($49,876,893)

Net income (loss) per common share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Basic

$0

($0.07)

$0

($0.10)

$0.01

($0.02)

($0.16)

($0.21)

'

($0.16)

($0.35)

'

'

'

'

'

'

'

'

Diluted

$0

($0.07)

$0

($0.10)

$0.01

($0.02)

($0.16)

($0.21)

'

($0.16)

($0.35)

'

'

'

'

'

'

'

'

Subsequent_Events_Details

Subsequent Events (Details) (Subsequent Event)	12 Months Ended
	Dec. 31, 2013
Subsequent Event	'
Subsequent Event [Line Items]	'
Stock Issued During Period, Shares, New Issues	23,473
Number of Common Stock to be purchased upon cashless exercise of options	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'4 years

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Details) (Deferred Tax Asset Valuation Account, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Deferred Tax Asset Valuation Account	'	'	'
Valuation And Qualifying Accounts Disclosure [Line Items]	'	'	'
Beginning Balance	$14,618,703	$11,004,790	$7,429,620
Charged to Costs & Expenses	3,161,558	3,613,913	3,575,170
Other Amounts	'	'	'
Deductions	'	'	'
Ending Balance	$17,780,261	$14,618,703	$11,004,790